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SUMMARY
Introduction The significance of ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin 
motif-13) activity for diagnosis and therapy of thrombotic thrombocytopenic purpura (TTP) and hemo-
lytic uremic syndrome (HUS) is still a controversial issue.
Objective The aim of this report was to analyze the value of ADAMTS13 measurements in the diagnosis 
of TTP and HUS.
Methods At presentation, we analyzed patients with idiopathic TTP (n=18), secondary TTP (n=4), diarrhea 
positive HUS (n=3) and diarrhea negative HUS (n=3) treated in Belgrade, Serbia from 2004 to 2010. AD-
AMTS13 activity from acute phase samples was measured using the residual collagen binding activity 
assay at the Haemophilia and Thrombosis Centre, Milan, Italy.
Results There was a significant correlation between reduced ADAMTS13 activity and idiopathic TTP 
diagnosis (p=0.000) as well as between lower ADAMTS13 activities and higher reticulocytes (p=0.017) 
and lactate dehydrogenase levels (p=0.027). Significant correlation was also found between higher pro-
tease activity and diagnosis of HUS (p=0.000). There was a statistically significant correlation between 
higher ADAMTS13 activities and higher platelets count (p=0.002), blood urea nitrogen (p=0.000), and 
creatinine level (p=0.000).
Conclusion Severe ADAMTS13 deficiency points at the diagnosis of idiopathic TTP and it is present in 
the secondary TTP but not in HUS.
Keywords: thrombotic thrombocytopenic purpura; hemolytic uremic syndrome; ADAMTS13; diagnosis
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INTRODUCTION
Thrombotic thrombocytopenic purpura (TTP) 
and hemolytic uremic syndrome (HUS) are 
manifestations of excessive microvascular 
platelet adhesion/aggregation, and present dan-
gerous thrombotic microangiopathies (TMA) 
with dramatic clinical presentation and some-
times fatal outcome, even with rapid diagnosis 
and proper therapy. Most frequently involved 
organs are the brain, kidneys, heart, spleen, 
pancreas, and adrenals [1, 2, 3].
The pathophysiology of TTP appears to 
involve the largest of the unusually large von 
Willebrand factor (ULvWF) polymers. Upon 
expression by endothelial cells, vWF is secreted 
into the circulation as ULvWF. Normally, these 
multimers are processed into smaller regular 
sized multimers in the high-shear environ-
ment of the arterial circulation which will not 
spontaneously react with platelets [1, 4]. The 
vWF processing activity is now known to be 
a specific vWF-cleaving metalloprotease in 
normal plasma that prevents persistence in 
the circulation of ULvWF multimers [5, 6]. 
Specific vWF-cleaving metalloprotease is 
characterized as a 13th member of a large ar-
ray of structurally related enzymes known as 
the ADAMTS (disintegrin and metalloprotease 
with thrombospondin type 1 repeats) family, 
and is denoted as ADAMTS13. In patients 
with TTP, processing of the ULvWF multim-
ers is impaired due to the deficiency of the AD-
AMTS13. This eventually results in formation 
of the characteristic blood clots found in the   
microcirculation [1, 4].     
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There are several types of TTP [7, 8]. Congenital chron-
ic relapsing TTP is associated with a severe constitutional 
deficiency of ADAMTS-13 due to inherited ADAMTS13 
gene defects (2% to 3% of patients) [9, 10]. Chronic relaps-
ing TTP usually manifests in childhood. If recognized early 
enough and treated successfully, it then recurs at approxi-
mately three-week intervals indefinitely. Recurrences are 
predictable enough that treatment with plasma infusion 
will prevent them [1, 7, 8].
A much more common are acquired forms of TTP. 
Pathophysiology of most acquired forms of TTP is related 
to autoantibodies against ADAMTS13 [1, 4, 5]. Acute idi-
opathic TTP is the most common type of TTP seen in clin-
ical practice. Single episode TTP occurs without a known 
cause and has no recurrence (about two thirds of patients). 
In the remainder, the disease recurs at intermittent and 
unpredictable intervals (intermittent or relapsing TTP) [1, 
8, 10]. Many patients with acquired idiopathic TTP have 
absent or severely reduced plasma ADAMTS13 activity 
during an initial episode as well as during later recurrenc-
es. In these patients, ADAMTS13 activity usually increases 
toward normal on recovery from a single or recurrent epi-
sode [1]. If an identifiable cause (infections, autoimmune 
conditions, lymphomas, cancer, chemotherapeutics, im-
munosuppressants, platelet aggregation inhibitors alloge-
neic hematopoietic stem cell transplantation, pregnancy) 
precipitates the illness it is classified as secondary [7, 8]. 
It has been considered that patients with secondary TTP 
almost never have severe ADAMTS13 deficiency [4].
TTP is one of the most difficult diagnoses for the clini-
cal hematologist to make, due to the rarity of the disease 
and the poor specificity of clinical and laboratory signs and 
symptoms. The incidence of idiopathic TTP is estimated 
to be 4.5/1 million person/year, being higher in blacks 
[10, 11]. Severe thrombocytopenia and microangiopathic 
hemolytic anemia – MAHA (without an alternative cause) 
along with neurologic symptoms and signs due to predom-
inantly ischemia or infarction of brain (in 50% to 71% of 
episodes), constitute the characteristic TTP clinical triad 
[1, 4]. Fever and/or renal dysfunction occur in a minor-
ity of these patients. Consumptive thrombocytopenia and 
MAHA, together with fragmented red cells in blood smear 
and elevated serum levels of lactate dehydrogenase, (LDH) 
provide the clinician with the most diagnostically useful 
laboratory signs [11].
In closely related HUS, ischemia is predominantly renal. 
HUS is clinically recognized by simultaneous occurrence 
of thrombocytopenia and MAHA along with acute renal 
failure [1, 12]. Approximately 50% of cases of acquired 
HUS appear after gastrointestinal infection caused by Sh-
iga toxin–producing Escherichia coli 0157:H7 (diarrhea 
associated hemolytic uremic syndrome – D+HUS or typi-
cal HUS or epidemic form) [4, 8]. HUS without antecedent 
diarrhea is referred to as “atypical HUS” (diarrhea negative 
hemolytic uremic syndrome – D-HUS or sporadic form). 
ADAMTS13 deficiency rarely if ever occurs in D+HUS. 
Patients with atypical HUS seldom have ADAMTS13 de-
ficiency and frequently turn out to have abnormalities in 
the regulation of the alternate complement pathway due 
to mutations in complement factor H, factor I, factor B, or 
membrane cofactor protein [1, 4, 8].
Although traditionally considered separate entities, the 
distinction between TTP and HUS remains a matter of 
controversy because both syndromes often overlap [2]. Se-
vere renal involvement in a patient with TTP or extrarenal 
manifestations in a patient with HUS can obfuscate clinical 
boundaries between the two syndromes [1].
TTP and HUS are clinical diagnosis [1]. As a practical 
matter, very few laboratories can perform ADAMTS13 as-
says rapidly enough, and the clinician must make a diag-
nosis and initiate therapy without this information. Three 
features of the classic pentad: renal involvement, neuro-
logic symptoms, and fever are not necessary in establish-
ing the diagnosis. Thus, the presence of thrombocytopenia 
and MAHA is sufficient for the diagnosis as not all other 
features are always present from the outset [4, 12, 13].
Although it has been proposed [14] that severe AD-
AMTS13 deficiency specifically defines TTP, the current 
prevailing opinion is that not all patients appropriately 
diagnosed with idiopathic TTP on the basis of clinical 
and laboratory symptoms and signs have severe protease 
activity [11]. On the other hand, total deficiencies of AD-
AMTS13 were observed in TTP forms secondary to other 
diseases or conditions [3]. In contrast to another largely 
accepted concept that patients with HUS have normal or 
moderately reduced ADAMTS13 activities, it has been 
demonstrated that reduced or undetectable levels of pro-
tease activity were present in plasma of some patients clini-
cally diagnosed as having HUS [3, 15]. These provocative 
findings supported the views that these two syndromes 
should be identified clinically as TTP-HUS [2, 16].
It is well documented in TTP patients that early recog-
nition and diagnosis as well as timely treatment with plas-
ma exchange (PE) as the first-line therapy reduce mortal-
ity rate with long-term remission of 80-90%. The pres-
ence of antibodies of ADAMTS13 and the accumulation 
of ULvWF multimers in the patient’s plasma of acquired 
disease types suggest that the removal of such pathologic 
entities with PE would result in improvement of patients. 
The use of fresh frozen plasma (FFP) as the replacement 
fluid has the added benefit of infusing normal donor AD-
AMT13. In patients without antibodies to the cleaving 
protease (congenital TTP), only 10 to 15 mL/kg of FFP 
infused every 2 to 3 weeks can achieve remission [1, 2, 
7, 8, 12, 17, 18, 19]. Alternative therapeutic approaches, 
mainly based on immunosuppressive agents, have been 
used for resistant patients, but there is still no consensus 
as to the best approach [13]. Furthermore, some patients 
with HUS improved in association with PE. It is therefore 
appropriate to urgently commence daily PE procedures 
for all adult patients and older children with a clinical 
diagnosis of TTP or HUS [1].
OBJECTIVE
In 28 patients with TTP and HUS we evaluated the re-
lationship between diagnostic laboratory parameters and   
468
  
doi: 10.2298/SARH1308466V
Vučelić D. et al. Diagnostic Relevance of ADAMTS13 Activity: Evaluation of 28 Patients with TTP – HUS Clinical Diagnosis
clinical diagnosis, the value of ADAMTS13 measurements 
in establishing the diagnosis of TTP and HUS, and correla-
tion between ADAMTS13 activities and anti-ADAMTS13 
autoantibodies with standard diagnostic parameters.
METHODS
Patients
In a 6-year period (between August 2004 and February 
2010) 28 patients clinically diagnosed with TTP and HUS 
were admitted into three hospitals in Belgrade, Serbia: 
Clinic of Hematology - Clinical Centre of Serbia, Military 
Medical Academy, Mother and Child Health Care Institute 
of Serbia “Dr Vukan Čupić”. There were 22 female (78.6%) 
and 6 male (21.4%) patients included in this study. The 
median age was 39 years with a range of 17 to 68 years.
Clinical diagnosis
Clinical diagnosis was established based on the presence of 
MAHA (hemoglobin level bellow 120 g/L, elevated LDH, 
undetectable serum haptoglobin, evidence of erythrocytes 
fragmentation: at least 2 schistocytes per high-power field 
in peripheral blood smear, reticulocytosis, negative direct 
antiglobulin test), thrombocytopenia (platelet count less 
than 150×109/L), presence/absence of fever, presence/ab-
sence of neurological signs and symptoms, and presence/
absence of renal dysfunction/acute kidney injury (AKI) 
[20]. The measurements of laboratory parameters were 
performed according to the conventional methods using 
blood samples obtained on admittance. Table 1 presents 
the main patient’s clinical and laboratory characteristics 
at the time of diagnosis.
Idiopathic TTP was defined as TMA with predominant-
ly neurologic involvement occurring in patients with no 
apparent preexisting disease. Secondary TTP was defined 
as TMA with predominantly neurologic abnormalities in 
the presence of known predisposing conditions/precipi-
tants for disease onset: autoimmune disease, systemic dis-
ease, malignancy, bone marrow transplant. D+ HUS was 
defined as TMA with predominant clinical presentation 
of renal impairment/AKI associated with a prodromal 
diarrhea in patients with previously normal renal func-
tion. D- HUS in patients without prodromal diarrhea was 
defined as TMA with predominant clinical presentation 
of renal impairment/AKI in those with previously nor-
mal renal function [4, 21]. Diagnosis of AKI was made 
based on existing specific criteria introduced by the Acute 
Kidney Injury Network: rapid time course (less than 48 
hours), reduction in kidney function defined with absolute 
increase in serum creatinine of ≥0.3 mg/dl (≥26.4 μmol/l) 
or percentage rise in serum creatinine of ≥50% respectively 
as well as reduction in urine output defined as <0.5 ml/kg/
hr for more than 6 hours [22, 23]. In all patients with AKI 
diagnosis, renal function was previously normal. The diag-
nosis of the disease was made on clinical grounds without 
knowledge of the results of ADAMTS13 assays.
Clinical presentation was identified as idiopathic TTP 
in 18, secondary TTP in 4, D+HUS in 3, and D- HUS in 
3 patients. Secondary TTP was associated with systemic 
autoimmune diseases (patients No 19, 21, 22) and cancer 
(patient No 20). Patient No 19, 21, 22 were diagnosed with 
connective tissue systemic disease, syndrome sicca and sys-
temic lupus erythematosus (SLE). One patient (patient No 
25) defined as having D+HUS was on tacrolimus regular 
intake due to allogenous stem cell transplantation 3 years 
ago. One patient (patient No 27) with D-HUS exhibited 
onset of disease in the context of SLE.
ADAMTS13 activity measurement
Plasma samples were collected on admission. The AD-
AMTS13 activity was measured at the Angelo Bianchi 
Bonomi Haemophilia and Thrombosis Centre in Milan, 
Italy.
ADAMTS13 activity was assayed using collagen bind-
ing enzyme immunoassay. The source of VWF used as 
protease substrate was a purified VWF concentrate (Fac-
teur Willebrand Humain Tres Haute Purité) provided by 
Laboratoire Francais du Fractionnement et des Biotech-
nologies (Lille, France). The product, which lacks endog-
enous ADAMTS13 activity, was reconstituted to a VWF 
concentration of 100 U/mL, aliquoted and stored at -30°C. 
The concentrate was then thawed, diluted 1 in 33 with 5 M 
urea in 5 mM Tris-HCl, pH 8, and incubated for 10 min at 
room temperature. Subsequently, 50 μL of the dilution of 
the VWF source were added to 100 μL of serial dilutions 
(1/10, 1/20, 1/40) of test plasma as a source of ADAMTS13. 
Test plasmas were diluted in 5 mM Tris-HCl, pH 8 con-
taining 12.5 mM BaCl2 and 1 mM Pefabloc SC (Roche, 
Mannheim, Germany). Values were expressed as percent-
ages of pooled normal plasma. The most recent laboratory 
evaluation of assay reproducibility yielded an intra-assay 
coefficient of variation of 9% and an inter-assay coefficient 
of variation of 12%. The lower limit of sensitivity was 6% of 
protease levels in pooled normal plasma taken as the ref-
erence standard. The lower value of the reference interval 
(46%) was set at the 5th percentile of the distribution of the 
values obtained in 200 healthy individuals [24].
Anti-ADAMTS13 antibodies testing
Anti-ADAMTS13 antibodies were detected by western blot 
analysis, as previously reported [24].
In this study, ADAMTS13 activities were arbitrarily di-
vided into four categories, similar to the practice of some 
others authors [16]. The categories were as follows: 1. less 
than 6% which is the detection limit of the assay (severe 
deficiency); 2. between 6% and 25% (moderate deficiency); 
3. between 26% and 46% (mild deficiency); 4. greater than 
46% (normal).     
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Statistical analysis
Data were entered into a program SPSS for Windows 
version 18 and Statistica version 6.0. Variables were ana-
lyzed by using Chi-square test, Student t-test, Pearson’s 
correlation coefficient test, and Spearman’s rank correla-
tion test. P values <0.05 and <0.01 were considered to be 
significant.
RESULTS
Clinical presentation
Among 28 acute episodes, 25/28 patients presented with 
their initial TTP or HUS episode, whereas 3/28 patients 
(cases No 5, 13, 16) with idiopathic TTP experienced their 
first relapse after 11, 7, and 6 years from initial episode.
On diagnosis of 28 acute episodes, patients had multi-
ple presenting symptoms and signs. Thrombocytopenia 
and MAHA were present in all patients. Of 18 idiopathic 
TTP acute episodes, heterogeneous neurological abnor-
malities were the paramount presenting symptoms oc-
curring in 14 (77.7%) patients. The structure of central 
nervous system (CNS) abnormalities included headache, 
parestesias/paresis/numbness, disorientation/modified 
behavior, dysphasia/aphasia, hallucination, seizures, and 
stupor/coma. Headache was the most frequent symptom 
occurring in 12 patients (66.6%). Fever was present in 11 
(61.1%) cases. Renal dysfunction, in the absence of AKI, 
presented with alterations of urinanalysis, such as micro-/
macroscopic hematuria, proteinuria as well as moderately 
elevated blood urea nitrogen (BUN) and creatinine lev-
els was manifested in 13 (72.2%) patients; some of them 
(2/13; 15.4%) experienced lumbal pain.
Among 4 patients with secondary TTP, CNS abnormal-
ities (headache, slurred speech, disorientation, paresthe-
sias, bihemiparesis, sensomotor polyneuropathy, seizures, 
somnolence/stupor/coma) were present in 3 (75%), fever 
in 1 (25%), and mild renal impairment in 3 (75%) patients.
In the subgroup of 3 patients classified as having 
D+HUS, CNS abnormalities were absent in all of them 
while fever was present in 2 (66.6%) patients. AKI was 
manifested in 2 patients.
In the subgroup of 3 patients classified as having atypi-
cal HUS, all of them exhibited AKI. Headache and blurred 
vision were present in 1 patient. Also, one of them mani-
fested fever.
Laboratory parameters
Laboratory parameters, median values, and standard 
deviations among the subgroups of patients classified as 
having idiopathic TTP (N=18), secondary TTP (N=4), 
D+HUS (N=3) and D- HUS (N=3) are listed in Table 2. 
Haptoglobin was undetectable in all patients (data not 
shown).
Relation of standard laboratory diagnostic 
parameters to TTP and HUS clinical type
The relationship between diagnostic laboratory param-
eters and the clinical diagnosis showed statistically signifi-
cant differences (p<0.01) for the mean values of platelets, 
reticulocytes, BUN and creatinine. These results indicate 
that observed average values for platelets, BUN and cre-
atinine were significantly higher (p<0.00001, p<0.00001, 
p<0.00001) whereas reticulocytosis was found to be sig-
nificantly lower (p=0.007) among the patients clinically 
diagnosed with HUS compared to patients diagnosed   
with TTP.
Relationship between ADAMTS13 activity and  
TTP and HUS clinical diagnosis
ADAMTS13 activities being measured in samples collect-
ed from all patients on presentation are described in Table 
3. The samples were tested in acute phase of the disease.
Severe ADAMTS13 deficiency was detected in patients 
with idiopathic (13/18) and secondary TTP (1/4). In the 
category of moderate protease deficiency there were 2/18 
patients with idiopathic and 3/4 patients with secondary 
TTP. A mildly reduced ADAMTS13 activities were found 
in 3/18 patients with idiopathic TTP and 2/3 patients with 
D-HUS. Normal protease levels were measured only in 
the cases with HUS. In all patients with D+HUS protease 
levels were normal.
Thus, none of the patients with idiopathic and second-
ary TTP had normal and none of those with HUS had 
severe/moderate ADAMTS13 activity.
There was a significant correlation between reduced 
ADAMTS13 activities and idiopathic TTP clinical diag-
nosis (r=0.631; p<0.00001). A significant correlation was 
obtained in a relationship of higher protease activities with 
HUS clinical diagnosis (r=0.701; p<0.00001).
Table 2. Laboratory results on diagnosis (N=28)
Laboratory tests
Clinical type
Idiopathic TTP Secondary TTP D+ HUS D- HUS
Plt (×109/L) 3-80 (23.3±18.4) 10-54 (29±22) 21-95 (50.6±31.9) 47-121 (89.6±31.2)
Hb (g/L) 65-117 (84.9±15.3) 52-109 (77±27.6) 81-106 (94.3±10.3) 71-98 (85±11)
Ret (%) 4.6-19 (10.1±4.6) 4-20 (12.7±7.1) 2-10 (6± 3.2) 1-7 (3.9±2.45)
LDH (U/L) 602-4789 (2316±1333) 1187-4199 (2337.2±1440.3) 925-2057 (1511±463) 790-1088 (957.3±124.4)
Cr (µmol/L) 41-183 (90.1±37.9) 77-107 (95.5±13.5) 378-813 (540±194.1) 258-1221 (704.6±396.2)
BUN (mmol/L) 3-24.3 (8.3±5.7) 9.2-29.9 (16.3±9.5) 33-65.6 (47.4±13.5) 25.7-50.9 (40.5±10.7)
TTP – thrombotic thrombocytopenic purpura; D+ HUS – diarrhea positive hemolytic uremic syndrome (HUS); D- HUS – diarrhea negative HUS
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Relationship between anti-ADAMTS13 antibodies 
and TTP or HUS clinical diagnosis
Anti-ADAMTS13 antibodies were demonstrable in a total 
of 17/28 (60.7%) patients. The antibodies were identified 
among the patients that were categorized as having re-
duced protease activities. In the category of normal pro-
tease activity antibodies were not present (Table 4).
The antibodies were detected in 15/18 (83.3%) patients 
diagnosed with idiopathic TTP. In plasma of all patients 
(13/18; 72.2%) with idiopathic TTP and severe defi-
ciency of ADAMTS13 antibodies were present. Among 
the remaining patients with idiopathic TTP, antibodies 
were present in 2/3 (11.1%) patients in category of mild 
protease activity. The patients with idiopathic TTP and 
moderate protease activity (2/18) had no demonstrable 
antibodies.
Among the patients with secondary TTP forms anti-
bodies were detected in plasma of patient with SLE-as-
sociated disease with severe ADAMTS13 activity and in 
plasma of patient with syndrome sicca-related form with 
moderately reduced protease activity. Patients with under-
lying cancer and connective tissue systemic disease had no 
detectable antibodies.
In acute episode there was a significant link (r=0.533; 
p=0.003) of anti-ADAMTS13 antibodies presence with 
idiopathic TTP. Presence of antibodies was more frequent 
in idiopathic compared with other clinical forms. None of 
the patients with HUS had antibodies.
Analysis of laboratory diagnostic parameters 
in relation to protease activities and antibodies 
presence
Statistically significant correlations were obtained between 
higher ADAMTS13 activities and greater platelets number 
(r=0.568; p=0.002), BUN (r=0.717; p<0.00001), and cre-
atinine levels (r=0.701; p<0.00001).
On the other hand, a significant correlations were dem-
onstrated between lower ADAMTS13 activities and higher 
reticulocytes (r=0.448; p=0.017) and LDH levels (r=0.417; 
p=0.027).
In terms of antibodies presence/absence, statistically 
significant correlations were obtained between antibodies 
presence and lower platelets number (r=0.491; p=0.008) as 
well as higher reticulocytes (r=0.485; p=0.009).
There was significant link between the absence of anti-
bodies and higher BUN (r=0.666; p<0.00001) and creati-
nine (r=0.602; p=0.001) levels.
DISCUSSION
In our patients, searching for statistical relationship be-
tween standard laboratory diagnostic parameters and TTP 
and HUS clinical diagnosis revealed differences across clin-
ical type. There was a significant link between severity of 
renal function impairment i.e. clinical diagnosis with HUS 
and higher average values for platelets, BUN and creatinine 
as well as a relationship between higher reticulocytosis and 
TTP clinical diagnosis. These findings are in agreement 
with defining diagnostic features of TTP and HUS con-
sidering HUS description as a syndrome characterized by 
moderate thrombocytopenia (mean platelets number of 
36x109/L) and hemolysis with predominant renal abnor-
malities, and TTP as a syndrome with severe thrombocy-
topenia and excessive hemolysis, respectively [8, 12, 21].
In this study, we found that decreased levels of AD-
AMTS13 were present in all patients (N=22) given diag-
nosis TTP, either primary or secondary forms. The preva-
lence of reduced ADAMTS13 activities was significantly 
higher in patients clinically diagnosed with idiopathic 
TTP. The great majority of the patients clinically diag-
nosed with idiopathic TTP (72.2%), had undetectable 
protease activity. On the whole, the results of protease 
activities in acute idiopathic TTP obtained in this small 
cohort are partially in concur with original findings [4, 
5] but are in agreement with some others [24, 29, 35, 43]. 
Publications of Tsai and Lian [5] and Furlan et al. [6] in-
dependently found that the levels of plasma vWF cleaving 
protease were greatly reduced or absent during acute TTP 
episodes, with a return to a baseline values after recovery. 
They have detected autoantibody directed against the pro-
tease. The lock of cleaving protease was also determined 
in congenital TTP form, but in the absence of specific au-
toantibody. On the other hand, in patients with HUS, vWF 
cleaving protease activities were normal or only moder-
ately reduced. Veyrader et al. [3] investigated multicenter 
prospective cohort of 111 patients (66 manifesting as TTP 
and 45 as HUS). They found normal ADAMTS13 level in 
some patients with idiopathic TTP, and decreased protease 
level in some patients with HUS. Among patients with idi-
opathic TTP and decreased protease level, in around one 
third of them partial deficit was observed. In Vesely et al. 
[16] prospective study of 142 TTP-HUS patients, among 
48 patients within the clinical category of idiopathic TTP, 
only 16 (33.3%) of them had severe protease deficiency. 
Table 3. ADAMTS13 functional activity in acute TTP and HUS episodes 
(N=28)
Clinical type
ADAMTS13
<6% 6–25% 26–46% >46%
N % N % N % N %
Idiopathic TTP 13 72.2 2 11.1 3 16.7 0 0
Secondary TTP 1 25.0 3 75.0 0 0 0 0
D+HUS 0 0 0 0 0 0 3 100.0
D-HUS 0 0 0 0 2 66.7 1 33.3
Table 4. Anti-ADAMTS13 antibodies in the frame of clinical diagnosis 
and different categories of protease level (N=28)
Disease
Anti- 
ADAMTS13 
antibodies
ADAMTS13
<6% 6–25% 26–46% >46%
N % N % N % N %
Idiopathic TTP
Absent 2 1
Present 13 72.2 2 11.1
Idiopathic TTP
Absent 2
Present 1 25.0 1 25.0  
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Also, severe protease deficiency occurred among 2/10 
women in immediate postpartum period of their first preg-
nancy. None of the patients with HUS and secondary drug 
associated TTP-HUS had severe protease deficiency. Pey-
vandi et al. [25] prospectively analyzed 100 patients with 
TTP. Nearly one third of the patients (28/100, 28%) had 
normal ADAMTS13 activities. Only approximately half of 
the patients (48/100, 48%) had very low levels (<10%) of 
ADAMTS13 activity. Moderately reduced protease levels 
were detected in 24/100 (24%) patients.
In our patients, severe ADAMTS13 deficiency was 
associated with the presence of specific antibodies in all 
patients suggesting the principal involvement of immune 
pathomechanism. Overall frequency of specific antibodies 
in our idiopathic TTP patients was 83.3% (15/18) with the 
presence of antibodies in all patients in severe ADAMTS13 
deficiency category. Veyrader et al. [3] detected inhibitors 
in 31/65 (48%) patients with reduced ADAMTS13 activi-
ties. Inhibitors were observed only in patients with severe 
ADAMTS13 deficiency. In Vesely et al. [16] study, anti-
ADAMTS13 antibodies were measured in 17/18 (94%) 
patients with severe protease deficiency. In Peyvandi et al. 
[25] study, in more than half of patients ADMTS13 defi-
ciency was not associated with the presence of inhibitors.
Of the remaining our patients, two had moderately 
and three mildly decreased ADAMTS13 activity associ-
ated with the presence of antibodies in two patients with 
mildly protease deficiency. The finding of antibodies in the 
plasma of patients with incomplete inactivated antigen is 
consistent with previous report that postulated incomplete 
inactivation of antigen as possible explanation for the par-
tially reduced protease level with specific antibodies [25]. 
Severe ADAMTS13 activity secondary to the presence of 
antibodies was also found in one of our patients with sec-
ondary TTP and underlying SLE which is in correspond-
ence with previous report [3]. Among the secondary forms 
partial protease deficiency without antibodies were dem-
onstrated in two cases suggesting the influence of others 
possible mechanisms formerly proposed. These include: 
the presence of platelet aggregating factors, antibodies to 
platelets, antibodies to endothelial cells, endothelial injury, 
increased level of plasminogen activator inhibitor type 1 
(PAI-1) and genetic factors [26-30].
Unlike TTP, in our patients normal ADAMTS13 val-
ues were predominant in patients diagnosed with HUS: 
in samples of all patients with D+HUS, and one patient 
with D-HUS (33.3%). Protease activities in the absence of 
antibodies were only slightly decreased in 2/3 (66.6%) pa-
tients with D-HUS. A significant correlation was obtained 
in a relationship of higher protease activities with HUS 
clinical diagnosis. The findings in our HUS patients are 
in accordance with generally accepted opinion relying on 
the majority of literature data [3, 5, 6, 16, 25].
Concerning the correlation between ADAMTS13 activ-
ity and laboratory characteristics we found significance 
referred to the correlation of higher ADAMTS13 activities 
and greater platelets number, BUN, and creatinine levels. 
Moderate thrombocytopenia as well as significant incre-
ment of BUN and creatinine values are criteria for HUS, 
and actually in this entity normal/mildly reduced activi-
ties of ADAMTS13 are registered in our study. In contrast, 
significant correlations were demonstrated between lower 
ADAMTS13 activities and higher reticulocytes and LDH 
levels. Severe thrombocytopenia/hemolysis with high el-
evation of LDH and substantial bone marrow response de-
fine TTP in our study. These findings indicate that in the 
majority of patients two syndromes may be discriminated 
based on either the values of laboratory parameters and 
ADAMTS13 activity.
CONCLUSION
In this study, we found that reduced ADAMTS13 activ-
ity characterizes both primary and secondary TTP with 
significantly high association of severe protease deficien-
cy with idiopathic TTP. Conversely, normal ADAMTS13 
activity points to the diagnosis of typical HUS but is not 
present in idiopathic and secondary TTP. Either normal or 
slightly reduced protease activity in the absence of specific 
antibodies defined atypical HUS. ADAMTS13 deficiency 
was associated with the severity of hemolysis and TTP 
clinical diagnosis with predominantly neurological abnor-
malities whereas patients diagnosed as HUS with normal/
mildly reduced protease level manifested more impaired 
kidney function.
REFERENCES
1.  Moake JL. Thrombotic Thrombocytopenic Purpura. In:  
Kitchen CS, Alving BM, Kessler CM, editors. Consultative  
Hemostasis and Thrombosis. Philadelphia: Saunders; 2007.  
p.405-20.
2.  Mannucci MP. Thrombotic thrombocytopenic purpura and the 
hemolytic uremic syndrome: much progress and many remaining 
issues. Haematologica. 2007; 92:878-80.
3.  Veyraider A, Obert B, Houllier A, Meyer D, Girma JP. Specific 
von Willebrand factor-cleaving protease in thrombotic 
microangiopathies: a study of 111 cases. Blood. 2001;  
98:1765-72.
4.  Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic 
thrombocytopenic purpura. Blood. 2008; 112:11-8.
5.  Tsai HM, Lian EC-Y. Antibodies to von Willebrand factor-cleaving 
protease in acute thrombotic thrombocytopenic purpura. N Engl J 
Med. 1998; 339:1585-94.
6.  Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, 
et al. von Willebrand factor-cleaving protease in acute thrombotic 
thrombocytopenic purpura and the hemolytic-uremic syndrome. N 
Engl J Med. 1998; 339:1578-84.
7.  Suvajdžić-Vuković N. The role of von Willebrand protease in 
aetiopathogenesis of thrombotic thrombocytopenic purpura. Srp 
Arh Celok Lek. 2007; 135:360-6.
8.  Myers L. Thrombotic thrombocytopenic purpura-hemolytic uremic 
syndrome: pathophysiology and management. Nephrol Nurs J. 
2002; 29:171-82.
9.  Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, 
et al. Mutations in a member of the ADAMTS13 gene family cause 
thrombotic thrombocytopenic purpura. Nature. 2001; 413:488-94.
10.  Peyvandi F, Palla R, Lotta LA. Pathogenesis and treatment of 
acquired idiopathic thrombotic thrombocytopenic purpura. 
Haematologica. 2010; 95:1444-7.
Vučelić D. et al. Diagnostic Relevance of ADAMTS13 Activity: Evaluation of 28 Patients with TTP – HUS Clinical Diagnosis     
473 Srp Arh Celok Lek. 2013 Jul-Aug;141(7-8):466-474
www.srp-arh.rs
11.  Mannucci MP, Peyvandi F. TTP and ADAMTS13: When Is Testing 
Appropriate? Hematology Am Soc Hematol Educ Program. 
2007:121-6.
12.  George JN. How I treat patients with thrombotic thrombocytopenic 
purpura-hemolytic uremic syndrome. Blood. 2000; 96:1223-9.
13.  Suvajdžić-Vuković N, Budišin Ž, Elezović E. The successful treatment 
of refractory thrombotic thrombocytopenic purpura with 
vincristine: a case report. Haema. 2005; 8:300-3.
14.  Tsai HM. Is severe deficiency of ADAMTS-13 specific for  
thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost. 
2003; 1:625-31.
15.  Loof AH, van Vliet HH, Kappers-Klunne MC. Low activity of von 
Willebrand factor- cleaving protease is not restricted to patients 
suffering from thrombotic thrombocytopenic purpura. Br J 
Haematol. 2001; 112:1087-8.
16.  Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El Hanake MA, 
et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-
hemolytic uremic syndrome: relation to presenting features and 
clinical outcomes in a prospective cohort of 142 patients. Blood. 
2003; 102:60-8.
17.  Rock GA, Shumak KH, Buskard NA, Blanchete VS, Kelton JG,  
Nair RC, et al. Canadian Apheresis Study Group. Comparison 
of plasma exchange with plasma infusion in the treatment of 
thrombotic thrombocytopenic purpura. N Engl J Med. 1991; 
325:393-7.
18.  Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in 
thrombotic thrombocytopenic purpura-hemolytic-uremic 
syndrome. Clinical experience in 108 patients. N Engl J Med. 1991; 
325:398-403.
19.  Suvajdžić-Vuković N, Pandurović R, Rajić Z, Milosević R, Bogdanović 
A, Lazarević V, et al. Treatment of 36 cases of thrombotic 
thrombocytopenic purpura.Vojnosanit Pregl. 2004; 61:621-7.
20.  Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: 
report of 16 cases and review of the literature. Medicine (Baltimore). 
1966; 45:139-59.
21.  Alford SL, Hunt BJ, Rose P, Machin SJ on behalf of Hemostasis and 
Thrombosis Task Force of the British Committee for Standards in 
Haemathology. Guidelines on the diagnosis and management 
of the thrombotic microangiopathic hemolytic anaemias. Br J 
Haematol. 2003; 120:556-73.
22.  Webb S, Dobb G. ARF, ATN or AKI? It’s now acute kidney injury. 
Anaesth Intensive Care. 2007; 35:843-4.
23.  Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, 
et al. for the Acute Kidney Injury Network. Acute Kidney Injury 
Network: report of an initiative to improve outcomes in acute 
kidney injury. Critical Care. 2007; 11:R31.
24.  Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, 
Battaglioli T, et al. ADAMTS13 and anti-ADAMTS13 antibodies as 
markers for recurrence of acquired thrombotic thrombocytopenic 
purpura during remission. Haematologica. 2008; 93:232-9.
25.  Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM.  
Von Willebrand factor cleaving protease (ADAMTS13)and 
ADAMTS13 neutralizing autoantibodies in 100 patients with 
trombotic thrombocytopenic purpura. Br J Haematol. 2004; 
127:433-9.
26.  Murphy WG, Moore JC, Kelton JG. Calcium-dependent 
cysteine protease activity in sera of patients with thrombotic 
thrombocytopenic purpura. Blood. 1987; 70:1683-7.
27.  Moore JC, Murphy WG, Kelton JG. Calpain proteolysis of von 
Willebrand factor enhances its binding to platelet membrane 
glicoprotein Iib/IIIa: an explanation for platelet aggregation in 
thrombotic thrombocytopenic purpura. Br J Haematol. 1990; 
74:457-64.
28.  Burns ER, Zucker-Franklin D. Pathologic effects of plasma  
from patients with thrombotic thrombocytopenic purpura on 
platelets and cultured vascular endothelial cells. Blood. 1982; 
60:1030-7.
29.  Leung DY, Moake JL, Havens P, Kim M, Pober JS. Lytic anti-
endothelial cell antibodies in hemolytic uraemic syndrome. Lancet. 
1988; 2:183-6.
30.  Rock GA, Kelton JG, Kenneth H, Shumak KH, Noel A, Buskard NA, 
et al. Laboratory abnormalities in thrombotic thrombocytopenic 
purpura. Canadian Apheresis Group. Br J Haematol. 1998;  
103:1031-6.  
474
  
КРАТАК САДРЖАЈ
Увод Зна  чај ди  јаг  но  стич  ке спе  ци  фич  но  сти ак  тив  но  сти 
ADAMTS13 (енгл. A Dis in te grin And Me tal lo pro te i na se with 
Throm bo Spon din mo tif-13) у тром  бо  зној тром  бо  ци  то  пе  ниј-
ској пур  пу  ри (ТТП) и хе  мо  ли  зно-уре  миј  ском син  дро  му (ХУС) 
и да  ље је пред  мет рас  пра  ва.
Циљ ра  да Циљ ис  тра  жи  ва  ња је био да се ис  пи  та зна  чај ак-
тив  но  сти ADAMTS13 у ди  јаг  но  зи акут  ног ТТП-ХУС.
Ме  то  де ра  да Ис  пи  та  ни су бо  ле  сни  ци са иди  о  пат  ским ТТП 
(18 ис  пи  та  ни  ка), се  кун  дар  ним ТТП (4), ди  ја  ре  ја-по  зи  тив  ним 
(Д+) ХУС (3) и ди  ја  ре  ја-не  га  тив  ним (Д-) ХУС (3) ко  ји су ле-
че  ни у Бе  о  гра  ду у пе  ри  о  ду 2004–2010. го  ди  не. Ак  тив  ност 
ADAMTS13 ме  ре  на је у акут  ној фа  зи бо  ле  сти ме  то  дом ре  зи-
ду  ал  ног ко  ла  ген-ве  зу  ју  ћег иму  но  е  се  ја у Цен  тру за хе  мо  фи-
ли  ју и тром  бо  зу у Ми  ла  ну.
Ре  зул  та  ти До  би  је  на је ста  ти  стич  ки зна  чај  на удру  же  ност 
из  ме  ђу сни  же  не ак  тив  но  сти ADAMTS13 и иди  о  пат  ског ТТП 
(p=0,000), као и из  ме  ђу сни  же  не ак  тив  но  сти ADAMTS13 с јед-
не стра  не и ви  ших вред  но  сти бро  ја ре  ти  ку  ло  ци  та (p=0,017) 
и лак  тат-де  хи  дро  ге  на  зе (p=0,027) са дру  ге. Уоче  на је и зна-
чај  на ко  ре  ла  ци  ја из  ме  ђу ви  ших ак  тив  но  сти ADAMTS13 и 
ди  јаг  но  зе ХУС (p=0,000). Ста  ти  стич  ки зна  чај  на ко  ре  ла  ци  ја 
је за  бе  ле  же  на и из  ме  ђу ви  ше ак  тив  но  сти ADAMTS13 с јед  не 
стра  не и ви  ших вред  но  сти бро  ја тром  бо  ци  та (p=0,002), уре  је 
(p=0,000) и кре  а  ти  ни  на (p=0,000) са дру  ге.
За  кљу  чак Не  до  ста  так ADAMTS13 те  шког сте  пе  на го  во  ри у 
при  лог ди  јаг  но  зи иди  о  пат  ског ТТП и на  ла  зи се и у се  кун  дар-
ном ТТП, али ни  је од  ли  ка ХУС.
Кључ  не ре  чи: тром  бо  зна тром  бо  ци  то  пе  ниј  ска пур  пу  ра; хе-
мо  ли  зно-уре  миј  ски син  дром; ADAMTS13; ди  јаг  но  за
Дијагностичка применљивост активности ADAMTS13: процена код 
28 болесника са тромбозном тромбоцитопенијском пурпуром и  
хемолизно-уремијским синдромом
Драгица Вучелић1, Данијела Миковић2, Зоран Рајић3, Небојша Савић4, Живко Будишин5, Небојша М. Антонијевић6,7, 
Слободан Обрадовић8, Драгана Јевтић7,9, Роберта Пала10, Карла Валзеки10, Флора Пејванди10
1Клиника за дигестивну хирургију, Клинички центар Србије, Београд, Србија;
2Институт за трансфузију крви Србије, Београд, Србија;
3Клиника за хематологију, Клинички центар Србије, Београд, Србија;
4Клиника за васкуларну и ендоваскуларну хирургију, Клинички центар Србије, Београд, Србија;
5Универзитетска дечја клиника, Београд, Србија;
6Клиника за кардиологију, Клинички центар Србије, Београд, Србија;
7Медицински факултет, Универзитет у Београду, Београд, Србија;
8Клиника за ургентну медицину, Војномедицинска академија, Београд, Србија;
9Институт за здравствену заштиту мајке и детета Србије „Др Вукан Чупић“, Београд, Србија;
10Одељење за дијагностику и лечење коагулопатија, Центар за хемофилију и тромбозу „А. Бјанки Бономи“, Fondazione IRCCS Cà Granda 
– Ospedale Maggiore Policlinico, Универзитет у Милану и Фондација „Луиђи Вила“, Милано, Италија
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